Acorda Therapeutics (NSDQ:ACOR) said today that it plans to cut 20% of its workforce as a part of a cost reduction and restructuring effort. The move comes less than 1 week after the company lost patents related to its multiple sclerosis drug, Ampyra.
The Ardsley, N.Y.-based company had 597 employees as of February, according to Reuters, and the job cuts are expected to save more than $21 million annually.
Get the full story at our sister site, Drug Delivery Business News.
The post Acorda to cut 20% of staff in restructuring effort appeared first on MassDevice.